Agios Pharmaceuticals Inc (STU:8AP)
€ 45.8 0.8 (1.78%) Market Cap: 2.49 Bil Enterprise Value: 1.59 Bil PE Ratio: 4.05 PB Ratio: 1.61 GF Score: 28/100

Agios Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2021 / 01:20PM GMT
Release Date Price: €42.29 (-2.67%)
Mark Alan Breidenbach
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Good morning. And thanks so much for joining us on day 2 of Oppenheimer's 31st Annual Healthcare Conference. My name is Mark Breidenbach. I'm part of the Oppenheimer's biotech equity research team. And this morning, I'm pleased to be hosting a fireside chat with Agios, which is developing novel therapies for rare diseases.

We're joined today by the company's CEO, Jackie Fouse. And we might be joined in a little bit by CMO, Chris Bowden. We'll be sure to leave a few minutes at the end for Q&A. So I would encourage anyone in the audience who has a question to make use of the question box at the bottom of the -- of your video. So thanks everyone for joining in today. And let's go ahead and get started.

Questions & Answers

Mark Alan Breidenbach
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Jackie, I think it's fair to say, Agios stands out as one of the biggest pivot stories in biotech in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot